/

XFOR

X4 Pharmaceuticals, Inc.Closed

2.60−0.22 −7.80%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 2.62 +0.77%

Open

2.81

Prev close

2.82

Day range

2.592.82

52-week range

2.594.83

Volume

439.51K0.53×

Mkt cap

257.78M

P/E ttm

130.00

Fwd P/E

-3.39

EPS ttm

0.0200

Div yield

0.00%

Earnings

—

From 52w high

−46.17%

Price Chart

Yahoo Finance · delayed

XFOROct 13, 2026O 2.81H 2.83L 2.59C 2.60−0.22 (−7.80%)Vol 439.50K

SMA 503.64
SMA 2003.86

1Y change −15.03% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

XFOR X4 Pharmaceuticals, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −6.14%
1 month: −25.71%
3 months: −35.32%
6 months: −38.10%
Year to date: −35.00%
1 year: −15.03%

Valuation & ownership

Market cap: 257.78M
Enterprise value: 127.04M
P/E (ttm): 130.00
Forward P/E: -3.39
PEG ratio: —
Price / book: 1.61
Price / sales (ttm): 16.27
EV / EBITDA: -1.61
EPS (ttm): 0.0200
EPS (forward): -0.7675
Beta (5y monthly): 0.46
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 99.15M
Float: 57.23M
Short % of float: 7.67%
Short ratio (days): 6.42
Held by insiders: 0.44%
Held by institutions: 103.81%
Avg volume (3m): 835.20K
50-day average: 3.67
200-day average: 3.87
52-week change: −15.03%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 26.4
vs 50-day SMA: −28.63%
vs 200-day SMA: −32.73%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 7.37%
Realised vol (20d, ann.): 54.3%
From 52-week high: −46.17%
From 52-week low: +0.39%

ANR

Analyst Consensus

5 analysts

Consensus

—

Mean target

11.60

+346.15% implied

Low 10.00Median 12.00High 13.00

Recommendation trend

Now5 / 0 / 0
1m ago5 / 0 / 0
2m ago

DES

About X4 Pharmaceuticals, Inc.

Yahoo Finance profile

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 45
Headquarters: Boston, MA, United States
Website: x4pharma.com
Officers: Dr. Adam R. Craig M.B.A., M.D., Ph.D. Executive Chair
Mr. John P. Volpone M.B.A. President & COO
Mr. David H. Kirske CFO, Treasurer & Corporate Secretary
Dr. Richard Peters M.D., Ph.D.

SEAS

Seasonality · XFOR

2017–2026 · monthly returns

Strongest month Nov +16.13%Weakest month Jun −26.89%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-7.5	-7.0	20.1	-1.5	5.9	8.4	-14.8	1.5	-28.2	-10.3			−35.0%
2025	-4.6	-43.6	-40.3	-39.1	-21.1	-44.1	-11.6	123.5	-8.9	18.1	-9.9	9.9	−81.8%
2024	-6.9	24.3	43.2	-19.4	-9.8	-42.6	37.9	-12.5	-4.4	-25.3	-21.4	86.8	−12.5%
2023	3.7	-8.9	-7.2	69.0	38.1	-4.4	-7.7	-28.5	-14.8	-26.5	-2.6	7.6	−15.5%
2022	-10.0	-27.2	16.7	-26.3	-6.2	-20.2	32.6	-22.7	72.7	11.1	-21.1	-33.8	−56.6%
2021	21.5	22.5	-10.0	-2.7	13.4	-31.6	-11.5	-10.8	3.1	-8.5	-8.1	-48.5	−64.4%
2020	-22.4	28.7	-6.4	-6.9	-8.3	9.1	-20.4	12.9	-19.2	-15.2	15.0	-2.6	−39.9%
2019	17.7	1.1	5.1	17.2	-24.7	-2.4	-20.7	7.1	-0.3	-3.6	-13.2	0.7	−23.1%
2018	-1.2	17.0	55.2	-12.5	-14.0	-78.9	-30.6	-9.1	-29.3	-17.3	190.3	-40.4	−81.8%
2017												-24.4	−24.4%

INSD

Insider Activity · XFOR

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 30, 2026	Kirske David H. SrChief Financial Officer	Sale at price 2.86 per share.	11.8K	$33.66K
Aug 11, 2026	Craig Adam ROfficer and Director	Sale at price 4.44 per share.	47.4K	$210.83K
Aug 11, 2026	Volpone JohnPresident	Sale at price 4.44 per share.	24.6K	$109.23K
Jun 29, 2026	Kirske David H. SrChief Financial Officer	Sale at price 4.26 per share.	8.5K	$36.43K
May 11, 2026	Kirske David H. SrChief Financial Officer	Sale at price 4.29 per share.	17K	$72.82K
Oct 22, 2025	Craig Adam ROfficer and Director	Purchase at price 2.90 per share.	86.2K	$250.00K
Aug 13, 2025	Volpone JohnPresident	Stock Award(Grant) at price 0.00 per share.	289.9K	—
Aug 13, 2025	Craig Adam ROfficer and Director	Stock Award(Grant) at price 0.00 per share.	289.9K	—
Aug 13, 2025	Kirske David H. SrChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	193.3K	—
Jun 8, 2025	De Craecker FrancoiseDirector	Stock Award(Grant) at price 0.00 per share.	1.5K	—
Jun 8, 2025	Woods KeithDirector	Stock Award(Grant) at price 0.00 per share.	1.5K	—
Jun 8, 2025	Wyzga Michael SDirector	Stock Award(Grant) at price 0.00 per share.	1.5K	—
Jun 8, 2025	Mcgirr David W JDirector	Stock Award(Grant) at price 0.00 per share.	1.5K	—
Jun 8, 2025	Stewart MurrayDirector	Stock Award(Grant) at price 0.00 per share.	1.5K	—
Jun 8, 2025	Bridger Gary JDirector	Stock Award(Grant) at price 0.00 per share.	1.5K	—
May 19, 2025	Thoren Natasha FayOfficer	Stock Award(Grant) at price 0.00 per share.	3.3K	—
May 15, 2025	Baldry MarkOfficer	Purchase at price 2.48 per share.	1K	$2.56K
May 15, 2025	Baldry MarkOfficer	Stock Award(Grant) at price 2.48 per share.	1K	$2.56K
Feb 11, 2025	Dibiase MaryChief Operating Officer	—	650K	—
Feb 11, 2025	Baldry MarkOfficer	—	600K	—

13F

Investors Holding XFOR

latest 13F filings of 29 followed managers

Investors holding XFOR
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$84.5K	0.00%	18.10K	New	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

XFOR

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

XFOR

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About X4 Pharmaceuticals, Inc.

Seasonality · XFOR

Insider Activity · XFOR

Congress Trades · XFOR

Investors Holding XFOR

Investors Holding XFOR

Insider Activity · XFOR

Seasonality · XFOR

Congress Trades · XFOR

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About X4 Pharmaceuticals, Inc.

Financial Snapshot

Earnings & Dividends

News